AD-LIB.IO
12.5.2021 09:02:04 CEST | Business Wire | Press release
Ad-Lib.io , the next-generation Creative Management Platform for marketers at the world’s largest brands, today announced that it has been certified as a Google Marketing Platform (GMP) Partner in Spain, bringing Ad-Lib.io its sixth creative certification as it continues to extend its footprint across the globe.
The GMP Creative Certification in Spain affirms that Ad-Lib.io has demonstrated the ability to work within Google’s best practices and technology, and reinforces that its next-generation Creative Management Platform upholds high standards of service for creative design and process management. The certification reaffirms Ad-Lib.io’s successful client track record and its expertise across key capabilities including coding, asset delivery, and client services. The certification gives Ad-Lib.io , early access to product releases and announcements, and to a variety of other Google program resources.
“As the advertising industry emerges from a difficult year, advertisers are pushed to make their creative workflow more efficient while ensuring their ads stand out and perform well,” said Adit Abhyankar, CEO of Ad-Lib.io. “As a Google Marketing Platform Partner certified on the Creative tools, Ad-Lib.io offers advertisers in Spain on Google’s tech stack, the ability to easily and quickly build and activate content at scale, across formats and channels. Ad-Lib.io has been a trusted Google Partner since our founding in 2017 and we will continue to lead the way for advertisers that seek to produce and optimize relevant creative at scale.”
“As Google and its customers continue to find new ways to work together, partners like Ad-Lib.io are an important part of our ecosystem as they got certified.” according to Jose Maria Perez Sastre, Partnerships Manager at Google. “We are pleased that Ad-Lib.io continues to grow its presence and customers in Spain. We have seen great success already working together on clients in the region and we look forward to the continuing partnership in Spain and in other markets around the globe.”
This milestone strengthens Ad-Lib.io’s capability for customers working with the Google Marketing Platform in Spain and globally, as marketers seek solution providers that operate in the markets they serve. One partner with multi-region certifications, Ad-Lib.io is also a GMP Creative Partner in the United Kingdom, the United States, Dubai, Australia and Singapore.
“I'm very excited by the launch of another Google-certified market in Spain!” said Oli Marlow Thomas, founder of Ad-Lib.io. “This accompanies the awesome news that Ad-Lib.io DE is now up and running with former Googler Felix Derkum leading the charge. Ad-Lib.io is pushing into all parts of Europe.”
For more information about Ad-Lib.io, please visit: https://www.ad-lib.io/ .
About Ad-Lib.io
Ad-Lib.io provides the leading next-generation Creative Management Platform for marketers at the world’s largest brands to enable them to scale their digital creative. Ad-Lib.io connects creative and media workflows using intelligent automation, making it easy and fast to produce and optimize relevant ad creative across all digital channels. These ads are 60% more cost-efficient to produce, according to Ad-Lib.io’s customers which include 10 of the top 30 global brands. The venture-backed company -- recognized as a 2021 Start Up of the Year by Campaign Magazine -- was founded by former Google executives who understood the need to close the wide gap between creative concepts and digital media execution. Ad-Lib.io is headquartered in London, UK with offices in North America, Asia, Australia, Europe and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
